Paratek Pharmaceuticals Inc

Paratek Pharmaceuticals — Transcept Pharmaceuticals — Investor Presentation (May 2011)

54 slides from Paratek Pharmaceuticals's investor presentation, May 24, 2011

  1. Slide 1: Specialty pharmaceutical company focused on neuroscience

    Exhibit 99.1 A specialty pharmaceutical company focused on the development and commercialization of proprietary products to address important therapeutic needs in the field of neuroscience May 24, 2011

  2. Slide 2: Forward looking statements

    Forward looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. Examples of such statements include our expectat

  3. Slide 3: Introduction: Glenn A. Oclassen, CEO

    Introduction: Glenn A. Oclassen, CEO Transcept Pharmaceuticals

  4. Slide 4: Today's agenda

    Today’s agenda Welcome and introduction Glenn Oclassen, CEO Insomnia overview Andrew Krystal, MD – Definition, diagnosis and prevalence – Consequences and co-morbidities – Current treatment practices Middle of the night awakenings Thomas Roth, PhD – What are physicians and patients doing now? – Trea

  5. Slide 5: Andrew Krystal, MD, MS: professional biography

    Andrew Krystal, MD, MS: professional biography Professor, Department of Psychiatry Duke University Medical Center Director, Duke Sleep Research Laboratory, Insomnia Clinic, Quantitative EEG Lab, Brain Stimulation Research Program B.S. M.S. Biomedical Engineering, MIT M.D. and Psychiatry Residency, D

  6. Slide 6: Andrew Krystal, MD, MS: consulting relationships

    Andrew Krystal, MD, MS: consulting relationships Consultant: Abbott, Actelion, Astellas, Kingsdown, Arena, AstraZeneca, Axiom, Bristol-Myers Squibb, Cephalon, Eli Lilly, GlaxoSmithKline, Jazz, Johnson & Johnson, King, Merck, Neurocrine, Neurogen, Novartis, Organon, Pfizer, Philips/Respironics, Sanof

  7. Slide 7: Thomas Roth, PhD: professional biography

    Thomas Roth, PhD: professional biography Director of Sleep Medicine Henry Ford Hospital, Detroit Clinical Professor, Department of Psychiatry, University of Michigan Past President National Sleep Foundation, American Academy of Sleep Medicine, and Sleep Research Society Former Chair NIH National Cen

  8. Slide 8: Thomas Roth, PhD: consulting relationships

    Thomas Roth, PhD: consulting relationships Consultant: Abbott, Acadia, Acologix, Actelion, Alkermes, Alza, Ancile, Arena, AstraZeneca, Aventis, Baxter, Bristol-Myers Squibb, Cephalon, Cypress, Dove, Eisai, Elan, Eli Lilly, Evotec, Forest, GlaxoSmithKline, Hypnion, Intec, Jazz, Johnson & Johnson, Kin

  9. Slide 9: Transcept: preparing for Intermezzo commercialization

    Transcept: preparing for Intermezzo ® commercialization Therapeutic focus Neuroscience / psychiatry Large markets, Intermezzo ® : middle of the night awakenings unmet needs TO-2061 : treatment resistant OCD Commercial U.S. primary care partnership: Purdue Pharma platform Co-promote option 1 yr post

  10. Slide 10: High salivary pH induced by Intermezzo sublingual buffer system

    High salivary pH induced by Intermezzo ® sublingual buffer system facilitates penetration of zolpidem through oral mucosa H H N N CH O OH CH 3 3 N N H C OH H3 C 3 HO O O OH O N HC CH 3 Buffer combination N CH3 3 H3C 2 raises salivary pH to 9.5 Zolpidem tartrate salt form Zolpidem free base (hydrophi

  11. Slide 11: Intermezzo 3.5 mg delivered more zolpidem earlier than ~3x higher Ambien dose

    Intermezzo ® 3.5 mg delivered more zolpidem earlier than a ~3x higher Ambien ® dose PK comparison study: Intermezzo ® 3.5mg vs. Ambien 10mg PO (n=33) 1.5x 4 Intermezzo ® 3.5 mg 3 3.0x 2 1 9.6x Ambien® 10 mg 0 0 5 10 15 20 Time (min) 11

  12. Slide 12: Insomnia: Definition, diagnosis, prevalence

    Insomnia: Definition, diagnosis, prevalence Andrew Krystal, MD

  13. Slide 13: Insomnia overview

    Insomnia overview INSOMNIA - More than one type of disturbance may be present - Symptoms may vary over time Difficulty Falling Difficulty Staying Waking Too Poor Quality of Asleep Asleep Early Sleep (MOTN awakening) At least 3x per week At least 3x per week At least 3x per week At least 3x per week

  14. Slide 14: Sleep maintenance symptoms are the most commonly reported sleep problem

    Sleep maintenance symptoms are the most commonly reported sleep problem 70.0 60.0 50.0 40.0 30.0 20.0 10.0 0.0 Sleep onset Maintenance Early morning Non-restorative (MOTN awakening) awakening Sleep only Roth et al., Biological Psychiatry, 2011. 14

  15. Slide 15: Middle of the night awakening: #1 insomnia symptom

    Stanford Sleep Epidemiology Research Center: Middle of the night awakening: #1 insomnia symptom Population based epidemiology study: ~9,000 subjects over 4 years Persistence: - >90% report awakenings persist more than 6 months - 50% report awakenings persist more than 5 years Ohayon, et al., Nocturn

  16. Slide 16: Insomnia: consequences and co-morbidities

    Insomnia: consequences and co-morbidities Andrew Krystal, MD

  17. Slide 17: Consequences of insomnia

    Consequences of insomnia Days out of work or role >3x more for people with insomnia vs. people with no insomnia Prevalence of accidents or injury >1.5x greater for people with insomnia vs. people with no insomnia Walsh et al., World Association of Sleep Medicine, 2009. 17

  18. Slide 18: > 25% of days out of work are attributable to insomnia

    > 25% of days out of work are attributable to insomnia Accidents (%) Days out of role/30 days (%) Any insomnia 9.8 29.1 COPD 0.5 3.5 Diabetes 0.3 -1.5 Osteoarthritis -0.1 2.6 GERD 0.9 4.0 Sleep apnea -0.6 1.1 Neuropathic pain 2.6 2.9 Chronic heart failure 0.3 2.3 Climacteric symptoms 0.3 2.1 Hyperte

  19. Slide 19: Insomnia symptoms in common co-morbid conditions

    Insomnia symptoms in common co-morbid conditions MOTN patient demographics are similar to those of other insomnia patients, but comorbid conditions seem to vary by presentation. Insomnia presentation MOTN & MOTN only Bedtime only Bedtime N 240 170 370 Comorbid conditions: Depression 43.6% 42.5% 39.9

  20. Slide 20: Insomnia: Current treatment practices

    Insomnia: Current treatment practices Andrew Krystal, MD

  21. Slide 21: Patients with insomnia present this as a secondary complaint or not at all

    Patients with insomnia either present this as a secondary complaint or, not at all Discussed sleep problem during visit for other purposes 26% Visited Never specifically to discussed discuss sleep 69% problem 5% Ancoli-Israel et al., SLEEP, 1999. 21

  22. Slide 22: All currently approved sleep aids are indicated for bedtime administration only

    All currently approved sleep aids are indicated for bedtime administration only Drug (generic) Brand name Half-life (h) Doses (mg) Benzodiazepines Estazolam ProSom 8-24 1, 2 Flurazepam Dalmane 48-120 15, 30 Quazepam Doral 48-120 7.5, 15 Temazepam Restoril 8-20 7.5, 15, 22.5, 30 Triazolam Halcion 2-4

  23. Slide 23: Current dosing strategies for MOTN insomnia may promote prophylactic use

    Current dosing strategies for MOTN insomnia may promote prophylactic (every night) use Bedtime prophylactic dosing – The only current option/strategy • Approved hypnotics are indicated for bedtime use only – Only Ambien CR, Lunesta and Silenor are indicated for sleep maintenance • MOTN awakenings ge

  24. Slide 24: Middle of the night awakenings: what are physicians and patients doing now?

    Middle of the night awakenings: what are physicians and patients doing now? Thomas Roth, PhD

  25. Slide 25: No product is currently indicated for prn treatment at middle of the night awakening

    No product is currently indicated or suited for prn treatment at the time of a middle of the night awakening MOTN awakenings, like other insomnia symptoms, typically do not occur every night An ideal therapeutic: – Used only at the time patients need help returning to sleep, not every night in advan

  26. Slide 26: Physician data: most MOTN patients do not experience awakenings every night

    Physician data: most MOTN patients do not experience awakenings every night of the week Insomnia patient-record survey, n=890 Intermezzo ® outpatient study n=232 (MOTN patients) n=294 22.0% Patients selected for multiple every night 34.1% and prolonged awakenings 5 to 6 nights Mean of 4-5 awakenings

  27. Slide 27: Epidemiologic data: off-label use of bedtime hypnotics in the middle of the night

    Epidemiologic data: off-label patient use of bedtime hypnotics in the middle of the night is common 1,927 subjects who received a hypnotic Rx in last year Results: – ~11% of all hypnotic users sometimes take their sleep aid in the middle of the night in order to return to sleep – ~50% of those hypno

  28. Slide 28: Epidemiologic data: characteristics of patients taking hypnotics at bedtime vs MOTN

    Epidemiologic data: characteristics of patients taking hypnotics at bedtime vs MOTN Characteristics of middle of the night sleep problems prior to beginning medication use among respondents who take prescription sleep medication either exclusively at bedtime (n = 303) or MOTN(but nevertwicein a sing

  29. Slide 29: Intermezzo: Clinical Data

    Intermezzo ®: Clinical Data Thomas Roth, PhD

  30. Slide 30: Intermezzo proposed indication statement

    Intermezzo ® proposed indication statement Intermezzo ® (zolpidem tartrate sublingual tablet) is indicated for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep 30

  31. Slide 31: Intermezzo: anticipated to be the first sleep aid for use in the middle of the night

    Intermezzo ®: anticipated to be the first sleep aid for use in the middle of the night at the time of awakening Sublingual tablet dissolves in ~ 2 minutes Novel formulation pH drives zolpidem base, rapidly absorbed Low dose 28% of Ambien CR ® dose Sleep lab, objective data: 14 minute sleep Fast acti

  32. Slide 32: Intermezzo 3.5 mg delivered more zolpidem earlier than ~3x higher Ambien dose

    Intermezzo ® 3.5 mg delivered more zolpidem earlier than a ~3xhigher Ambien ® dose PK comparison study: Intermezzo® 3.5mg vs. Ambien 10mg PO (n=33) 1.5x 4 Intermezzo® 3.5 mg 3 3.0x 2 1 9.6x Ambien® 10 mg 0 0 5 10 15 20 Time (min) 32

  33. Slide 33: Intermezzo offers potentially significant reduction in patient exposure to zolpidem

    Intermezzo ® offers potentially significant reduction in patient exposure to zolpidem 7 x 12.5mg=87.5mg Hypothetical case based on 7 nights of prophylactic bedtime dosing of Ambien CR vs. 4 nights of dosing with Intermezzo® at the time a MOTN awakening occurs ~84% reduction in overall exposure 4 x 3

  34. Slide 34: Phase 3 sleep lab study

    Transcept PHARMACEUTICALS, INC,

  35. Slide 35: Proportion of patients asleep following a middle of the night awakening

    Intermezzo ®: proportion of patients asleep following a middle of the night awakening Phase 3 sleep lab study n = 82 75% 56% 28% 35

  36. Slide 36: Next-day residual effects of Intermezzo 1.75 mg and 3.5 mg vs. placebo

    Next-day residual effects of Intermezzo ® 1.75 mg and 3.5 mg vs. placebo Phase 3 sleep lab study n = 82 p<0.44 p<0.91 p<0.62 vs. vs. p<0.15 Placebo Placebo 70 vs. vs. 70 Placebo Placebo 60 61.88 61.59 60 62.35 64.25 60.57 63.56 50 50 40 40 30 30 20 20 10 10 0 0 Objective (DSST) Subjective (VAS) Plac

  37. Slide 37: Good or Excellent next day ratings

    Intermezzo ®: “Good” or “Excellent” next day ratings Phase 3 sleep lab study n = 82 p<0.009 vs. p<0.024 Placebo vs. 50 Placebo 51.3 p<0.001 vs. p<0.001 47.6 Placebo vs. p<0.017 Placebo 40 42.6 vs. Placebo NS 40.0 39.5 36.5 30 32.9 23.5 23.5 20 10 0 Sleep Quality Refreshing Sleep Ability to Function

  38. Slide 38: Intermezzo outpatient study

    Intermezzo® outpatient study

  39. Slide 39: Latency to Sleep Onset, weekly

    Intermezzo ®: Latency to Sleep Onset, weekly Phase 3 outpatient study n = 294 70 60 50 40 p<0.0001 vs. p<0.0001 30 Placebo vs. p<0.0001 p<0.0001 Placebo vs. vs. Placebo Placebo 20 10 0 Baseline week 1 week 2 week 3 week 4 ® Placebo Placebo Intermezzo Intermezzo® 3.53.5mg mg 39

  40. Slide 40: Average weekly treatment exposure

    Intermezzo ®: average weekly treatment exposure Phase 3 outpatient study n = 294 5 4 3 2 1 0 Placebo Placebo week 1 week 2 week 3 week 4 wk 1 wk 2 ® Placebo Placebo Intermezzo 3.5mg Intermezzo® 3.5 mg 40

  41. Slide 41: Intermezzo highway driving study

    Intermezzo® highway driving study

  42. Slide 42: Intermezzo highway driving study overview

    Intermezzo ® highway driving study overview Approximately 40 healthy adult volunteers Highway driving over a one-hour period Single-center (Maastricht), double-blind, randomized, placebo-controlled crossover design Key comparisons: – Intermezzo® 3.5mg vs. placebo, dosed 4 hours prior to driving – In

  43. Slide 43: Intermezzo highway driving study results

    Intermezzo ® highway driving study results 4 hrs after MOTN Intermezzo ® dosing – Test condition consistent with proposed label – Primary analysis (symmetry): no statistically significant effect – Secondary analysis (mean): statistically significant but small effect of 0.8 cm SDLP 3 hrs after MOTN I

  44. Slide 44: Mean change in SDLP (cm) and 95% confidence intervals

    Mean change in SDLP (cm) and 95% confidence intervals (cross-study comparison) ~ SDLP produced by BAC of 0.05% (1) 0.08% (2) Drug & dose Drive time (1) Mean change in SDLP produced Zaleplon 10mg 4-5 hrs I I by 0.05% blood alcohol is 2.4 cm Lormetazepam 1mg 10-11hrs I I (EU DUI concentration limit).

  45. Slide 45: Estimated probability of exceeding SDLP 2.5 cm threshold for various hypnotics

    Estimated probability of exceeding SDLP 2.5threshold cm for various hypnotics and 95% confidence intervals (cross-study comparison) Drug & dose Drive time SDLP 2.4 cm driving impairment Zaleplon 10mg 4-5 hrs I I associated with 0.05% blood alcohol Zaleplon 20mg 4-5 hrs I I ® Intermezzo 3.5mg 4-5 hrs

  46. Slide 46: Estimated probability of exceeding SDLP 4.0 cm threshold for various hypnotics

    Estimated probability of exceeding SDLP 4.0 cm threshold for various hypnotics and 95% confidence intervals (cross-study comparison) Drug & dose Drive time SDLP 4.2 cm driving impairment ® Intermezzo 3.5mg 4-5 hrs I I associated with 0.08% blood alcohol Zaleplon 10mg 4-5 hrs I I Zaleplon 20mg 4-5 hr

  47. Slide 47: Driving study results - labeling vs. approvability: HORIZANT

    Driving study results - labeling vs. approvability: HORIZANT ™ Prescribing Information HORIZANT™ (gabapentin enacarbil) NDA approval for the treatment of Restless Legs Syndrome: April 6, 2011 A nightly 1,200 mg dose of HORIZANT ™ produced significant impairment 14 hours after dosing in a driving sim

  48. Slide 48: Question & answer

    Transcept PHARMACEUTICALS, INC,

  49. Slide 49: Concluding remarks: Glenn A. Oclassen, CEO

    Concluding remarks: Glenn A. Oclassen, CEO

  50. Slide 50: Estimating the MOTN market size at branded prices

    Estimating the MOTN market size at branded prices Ohayon, et al., Nocturnal Awakenings in the American 235 M U.S. adults (1) x Ohayon General Population: Prevalence and Consequences (2) MOTN sufferers at least 3x week 83 M (2) …with difficulty returning to sleep 36 M (2) …without difficulty initiati

  51. Slide 51: Commercialization partnership with Purdue Pharma

    Commercialization partnership with Purdue Pharma Leading pain therapeutic franchise 2010 net revenue: ~$2.4 billion Branded products include: OxyContin®, MSContin®, Dilaudid®, Butrans® Sales force of >500 field reps calling on primary care physicians and high prescribing specialists High value pain

  52. Slide 52: Commercialization agreement: key Transcept benefits

    Commercialization agreement: key Transcept benefits Co-promote option: foundation for a commercial future – Transcept option: co-promote to psychiatrists as early as the first anniversary after Purdue launch Milestone payments – Upfront license fee: $25M received August 2009 – FDA approval milestone

  53. Slide 53: Transcept: preparing for Intermezzo commercialization

    Transcept: preparing for Intermezzo® commercialization Therapeutic focus Neuroscience / psychiatry Large markets, Intermezzo® : middle of the night awakenings unmet needs TO-2061 : treatment resistant OCD Commercial U.S. primary care partnership: Purdue Pharma platform Co-promote option 1 yr post In

  54. Slide 54: Trademark notices

    Intermezzo ® is a registered trademark of Transcept Pharmaceuticals, Inc. Ambien ® and Ambien CR ® are registered trademarks of sanofi-aventis Lunesta ® is a registered trademark of Sunovion Pharmaceuticals Inc. Zofran ® and Paxil ® are registered trademarks of The GlaxoSmithKline Group of Companies

Transcept Pharmaceuticals — Investor Presentation (May 2011) on 6ix